2Kneller A,Rasuda P,Hardan I.et a1.Therapy with thalidomide in refractory multiple myeloma patients the revival of an old drug.Br J Haematol,2000,108:39l-393.
3Gasparettoc.Stem cell transplantion for multiple myeloma.Cancer control,2004.1l:119-129.
4Aparicio A.Gardner A,Tu Y,el a1.In vitro cytoreductive effect on multiple myeloma cells induced by biophosphonates.Leukemia,1998,12:220-229.
5Matsui M,Huffc A.Vala M,et a1.Anti—tumoracrivity of interferon-alpha in multiple myeloma:role of interleukin 6 and tumor cell differentiation.Br J Haematol,2003,12l:251—258.
6Hussein M A,Saleh M.Ravand F,et a1.Phase 2 study pf arsenic trioxide in patients with replased or refractory multiple myeloma.Br J haematol.2004.125:470-476.
7Anderson K C.Boise I.H,I.ouie R.et a1.Arsenic trioxide in multiple myeloma:rationale and future directions.Cancer J,2002,8:12—25.
8Goldsehmidt H, Egerer G, Ho AD. Autologous and allogeneic stem eell transplantation in multiple myeloma. Bone Marrow Transplant. 2000,25(Supp12) : S25-26.
9Tricot G, Crowley J, Stover J, et al. Lack of Prognostic Implications of Induction Response to Total Therapy 2 (TT-2) in Newly Diagnosed Patients with Multiple Myeloma (MM) for Post-Transplant Even-Free Survival (EFS) and Overall Survival (OS). Blood, 2004,104(11):936-936.
10Harousseau JL, Attal M, Leleu X, et al. Bortezomib plus dexamethasone as induction treatment prior to autologous stem cell transplantation in patients with newly diagnosed multiple myeloma :results of an IFM phase Ⅱ study. Haematologica, 2006, 91(11):1498-1505.
